Revised pledge disclosure by Symbiotec Pharmalab promoters

Ownership Changes View source PDF Explain this filing

SYMBIOTEC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.3%Reaction day

₹1272.10

prior close

₹1268.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.7%-1.6% vs market

On the reaction day the stock moved 1.6 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.1

15m

+0.6

30m

+1.3

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

-3.3-1.7-1.6

Next day

-5.7-4.2-1.5

-6.0-5.2-0.8

-8.8-7.4-1.4

-3.7-7.0+3.4

+0.5pendingpending

———

15d

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Symbiotec Pharmalab filed a revised SAST disclosure, correcting its September 12, 2026 filing. The revision only adds the trustee name (Beacon Trusteeship) alongside the lender, Nomura Capital India. The underlying event is re-creation of pledge by promoters as security for debentures. Across 7 promoter entities, about 82.4 lakh shares (around 12.8 percent of capital) are pledged to Nomura Capital via Beacon Trusteeship. No change in pledged quantities or terms from the original filing.

Likely market impact

Technical correction only, no change in actual pledged shares. Combined promoter pledging stands at about 12.8 percent of capital, worth monitoring.